FY2019 · ended Dec 31, 2019 · Revenue $31,243, -83.3% YoY · Filed Mar 31, 2021
enVVeno Medical Corporation (NVNO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. Free cash flow was -$15.6 million. As of Sep 30, 2026 it held $18.5 million in cash and investments and $718,000 in total debt.
Revenue
$31,243
-83.3% vs prior year
Net income
$-19.47M
+10.8% vs prior year
Operating cash flow (TTM)
$-13.41M
+22.2% vs year-ago TTM
Free cash flow
$-15.57M
+7.7% vs prior year
EPS
$-33.06
+25.8% vs prior year
Dividend per share
None
Shares outstanding
655,521
-96.3% vs prior year
Net cash
$17.75M
as of Sep 30, 2026
Operating margin
-24566.5%
FY 2019
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NVNO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661053
- Former names
- Hancock Jaffe Laboratories, Inc. (until Sep 22, 2021)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M |
| Diluted EPS | -$33.06 | -$44.53 | -$1.91 | — | — |
| Operating cash flow | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M |
| Free cash flow | -$15.6M | -$16.9M | -$18.9M | -$15.7M | -$12.2M |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M |
| Stockholders' equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M |
| Cash and investments | $28.2M | $43.2M | $46.4M | $39.0M | $54.7M |
| Total debt | $700,000 | $1.1M | $1.4M | $1.7M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 14, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Apr 29, 2026 | Apr 29, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
All 415 enVVeno Medical Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.